The LiDCO products will be shown at the forthcoming Japanese Anesthetic Society Meeting in Kobe on the 7th – 9th of June.
Dr Terry O’Brien, CEO of LiDCO, commented: “We are delighted that our partner Argon Medical has successfully concluded the approval process in Japan and will be promoting the product in the very near future. Minimally invasive hemodynamic monitoring in Japan has a potential market value of US$285 million per annum. We greatly welcome the substantial market opportunity this presents for LiDCO’s fluid monitoring technology.”
George A. Leondis, President of Argon Medical Devices, Inc added: “We are pleased to have received this most important approval. This next generation technology expands our critical care portfolio, offering clinicians a versatile, new and more effective option in minimally invasive, hemodynamic monitoring.”